Methotrexate Afortas (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption reduces the synthesis of DNA, RNA, and proteins, particularly affecting rapidly dividing cells such as immune cells and cancer cells, thereby providing immunosuppressive and antineoplastic effects.

The specific dose of Methotrexate Afortas is determined by the prescribing clinician based on the patient’s condition, disease severity, renal and hepatic function, and other individual factors. Only a qualified healthcare professional should set the dosing regimen.

Methotrexate is classified as pregnancy category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and should be discontinued well before conception. Breastfeeding is also not recommended, as methotrexate can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Methotrexate is the most widely used folate antagonist and offers a broad therapeutic range across rheumatology and oncology. Compared with newer agents such as leflunomide or biologics, methotrexate is generally less expensive but may require more intensive monitoring for hepatic, renal, and hematologic toxicity.

Methotrexate Afortas should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Methotrexate Afortas is supplied as an oral tablet and is taken by mouth with water. The prescribing physician will advise whether it should be taken with food or on an empty stomach, and the exact dosing schedule, which may be weekly or as otherwise directed.

The most serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression, and renal failure. Patients should be monitored regularly for signs of organ dysfunction, and any symptoms such as persistent cough, jaundice, unexplained bruising, or decreased urine output should prompt immediate medical evaluation.

Methotrexate Afortas is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, patients with known hypersensitivity to methotrexate, and those receiving live vaccines. Caution is also advised for patients with pre‑existing blood dyscrasias or uncontrolled infections.